Navigation Links
Dipexium Pharmaceuticals Updates Locilex™ Development Activities and Announces 2011 Milestones
Date:4/4/2011

NEW YORK, April 4, 2011 /PRNewswire/ -- Dipexium Pharmaceuticals today provided an update of its development activities and announced its milestones to be achieved during 2011. Management announced that it has completed successfully initial six-months' stability testing on the original formulation of Locilex™ (pexiganan acetate 1% cream) and has moved on with its manufacturers to expand the batch size for clinical and commercial production.  In addition, the Company has received formal and clear clinical guidance from the FDA to support its Phase 3 clinical and regulatory pathway to resubmission of its new drug application (NDA) for Locilex™ in the U.S.

The Company also announced that its critical milestones for 2011 include the following:

  • Manufacturing:  The Company anticipates completing the work required to support its chemistry, manufacturing and controls (CMC) meeting with FDA in May 2011;
  • CMC Meeting:  The Company anticipates convening a CMC meeting with FDA in August 2011 to finalize the Company's manufacturing plans and use of product supply in the upcoming Phase 3 program;
  • Special Protocol Assessment (SPA) Filing:  The Company intends to file for a SPA designation in September 2011 shortly after the tentatively planned scheduled CMC meeting.

"Successfully achieving these value-inflection points should significantly reduce the risk associated with completing the drug development of Locilex™ and position the Company for further financing or other strategic alternatives," stated David P. Luci, Co-Founder & Managing Partner.

About Dipexium:

Dipexium Pharmaceuticals, LLC is an emerging biopharmaceutical company initially formed to complete the development and initiate the commercialization of Locilex™ (pexiganan acetate 1% cream), a novel, small peptide anti-infective agent. Locilex™ is formulated as a topical cream and, with its compilation of clinical data in over 1,100 evaluable patients to date, we believe Locilex™ will be indicated to treat patients with mild diabetic foot infection, an area of substantially unmet medical need.  With limited resource required to complete clinical development, management believes Locilex™ has peak year sales potential of hundreds of millions of dollars in the U.S. and separately in the EU.  

Dipexium was co-founded by Robert J. DeLuccia and David P. Luci, pharmaceutical executives who together have over 50 years experience in the healthcare industry sector.  

Dipexium implements a "de-risking strategy" designed to enhance value by achieving a series of near-term value inflection points for its products with significant commercial potential.  Executing the most direct regulatory/clinical pathway to market embraces four primary operating principles: (1) reducing the execution risk associated with selecting more comprehensive, costly and time consuming clinical and regulatory pathways, (2) achieving multiple, near-term, targeted value inflection points critical to corporate and business development for an emerging biopharmaceutical company, (3) successfully completing non-dilutive capital formation transactions, and (4) maintaining operational efficiencies through a virtual corporate business model which draws on the expertise of its managing partners and their broad network of drug development professionals; all to achieve the common goal of long-term drug development success.

By executing the most direct regulatory/clinical pathway and by selecting lower-risk, late-stage product candidates with significant commercial potential, Dipexium believes it can leverage a modest amount of capital into a multifold financial return in a relatively short timeframe.  With Locilex™, several value-creating milestones have already been achieved internally and by our predecessors and several near-term value-inflection points exist on what we believe is a relatively short pathway to approval for an early-stage company.

For additional information about Dipexium Pharmaceuticals or Locilex™, please visit: www.dipexiumpharmaceuticals.com or contact the Company as follows:

David P. Luci
Co-Founder & Managing Partner
Tel: (917) 533-1469


'/>"/>
SOURCE Dipexium Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
2. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
3. Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
4. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
5. Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
6. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
7. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
8. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
9. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 Vestagen Technical Textiles, ... performance apparel for healthcare and other demanding applications, today ... Executive Officer. He replaces Dale Pfost , PhD, ... Mr. Bold is also joining Vestagen,s Board of Directors. ... class of active barrier technologies that combines fluid repellent, ...
(Date:2/8/2016)... RICHMOND, Calif. , Feb. 8, 2016 /PRNewswire/ ... leader in therapeutic genome editing, announced that the ... the Company,s Investigational New Drug (IND) application for ... a life-long therapy for Mucopolysaccharidosis Type I (MPS ... and enables Sangamo to initiate a Phase 1/2 ...
(Date:2/5/2016)... , Feb. 5, 2016  Despite the recent explosion ... than other industries to embrace Big Data due to ... On the medical side, organizations have begun looking to ... clinical trials to adherence. --> ... firm Best Practices, LLC, Big Data has started informing ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... expansion into Canada to provide its range of unique and advantaged protective ... Quebec City that will provide bilingual customer service and marketing support. A new ...
(Date:2/8/2016)... ... February 08, 2016 , ... T.E.N., ... that nominations will be accepted February 8, 2016 through May 8, 2016 ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth ... incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially higher ... make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... The AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago ... about helpful interventions and causes of chronic illness in children. , Very recent articles ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... added Kybella® to his medical and surgical expertise. Technically known as deoxycholic acid ... medication used as a non-surgical alternative for reduction of fat below the chin ...
Breaking Medicine News(10 mins):